---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Corticosteroids"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Corticosteroids. Topics: Corticosteroid use and tapering: international consensus guidance, Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance, Daily rather than alternate-day dosing: British guideline update, and Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/corticosteroids"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Corticosteroids

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Corticosteroids

<a id="topic-2.2.2.1.2-1"></a>

### Corticosteroid use and tapering: international consensus guidance

> “Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.”
> “Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.2-2"></a>

### Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance

> “Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG”
> “In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.”
> “A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.”
> “In 75% of patients, steroids have an effect within 2–4 weeks.”
> “Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.2-3"></a>

### Daily rather than alternate-day dosing: British guideline update

> “The recommendation to prescribe daily steroids rather than the alternate day regimen is now standard practice.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

<a id="topic-2.2.2.1.2-4"></a>

### Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use).”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
